Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia

Journal of Clinical Pharmacology

Volumn 53, Issue 11, 2013, Pages 1155-1167

  Van Wart, Scott A ^a   Forrest, Alan ^a,c   Khariton, Tatiana ^b   Rubino, Christopher M ^a   Bhavnani, Sujata M ^a   Reynolds, Daniel K ^a   Riccobene, Todd ^b   Ambrose, Paul G ^a  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Acute bacterial skin and skin structure infections; Ceftaroline; Community acquired bacterial pneumonia; Population pharmacokinetics; Renal impairment

Indexed keywords

AZTREONAM; CEFTAROLINE; CEFTAROLINE FOSAMIL; CEFTRIAXONE; CLARITHROMYCIN; PRODRUG; VANCOMYCIN;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; COMPARTMENT MODEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; KIDNEY DYSFUNCTION; MONTE CARLO METHOD; MULTICENTER STUDY (TOPIC); PREDICTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN INFECTION;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS; CEFTAROLINE; COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA; POPULATION PHARMACOKINETICS; RENAL IMPAIRMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PNEUMONIA, BACTERIAL; SKIN DISEASES, BACTERIAL; YOUNG ADULT;

EID: 84892941977     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.153     Document Type: Article

References (25)

1. Laudano JB. Ceftaroline fosamil: A new broadspectrum cephalosporin. J Antimicrob Chemother 2011;66(Suppl. 3):iii11-18.
2. Teflaro [package insert]. St Louis, MO: Forest Pharmaceuticals, Inc.; May 2012.
3. Zinforo Summary of Product Characteristics. Sodertalje, Sweden: AstraZeneca AB; 2012.
4. Ge Y, Floren L, Redman R, et al. Singledose pharmacokinetics (PK) of ceftaroline (PPI0903) in healthy subjects. In: Abstracts of the FortySixth Interscience Conference on Antimicrobial Agents and Chemotherapy. 2006: A1936. San Francisco, CA; September 2006.
5. Ge Y, Redman R, Floren L, et al. The pharmacokinetics (PK) and safety of ceftaroline (PPI0903) in healthy subjects receiving multipledose intravenous (IV) infusions. In: Abstracts of the Fortysixth Interscience Conference on Antimicrobial Agents and Chemotherapy. 2006:A1937. San Francisco, CA; September 2006.
6. Ge Y, Thye D, Liao S, et al. Pharmacokinetics (PK) of ceftaroline (PPI0903) in subjects with mild or moderate renal impairment (RI). In: Abstracts of the FortySixth Interscience Conference on Antimicrobial Agents and Chemotherapy. 2006: A1939. San Francisco, CA; September 2006.
7. Riccobene T, Fang E, Thye D. A single and multipledose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects. In: Abstracts of the Fortyeighth Interscience Conference on Antimicrobial Agents and Chemotherapy. 2008: A 1888. Washington, DC; September 2008.
8. Riccobene T, Laudano JB, Fang E, et al. An openlabel pharmacokinetic, safety, and tolerability study of single intravenous doses of ceftaroline in subjects with normal renal function or severe renal impairment. In: Abstracts of the Annual Meeting of the American College of Clinical Pharmacy. 2009: 191E. Anaheim, CA; March 2009.
9. Riccobene T, Jakate A, Rank D, et al. An openlabel, pharmacokinetic, safety and tolerability study of singledose intravenous ceftaroline in subjects with endstage renal disease on intermittent haemodialysis. In: Abstracts of the Nineteenth European Congress of Clinical Microbiology and Infectious Diseases. 2009: P1455. Helsinki, Finland; May 2009.
10. Riccobene T, Jakate A, Rank D, Thye D. Openlabel pharmacokinetic, safety, and tolerability study of single intravenous doses of ceftaroline in healthy elderly and healthy young adult subjects. In: 44th Annual Meeting of the American Society of HealthSystem Pharmacists (ASHP). 2009. Las Vegas, NV; December, 2009.
11. Talbot GH, Thye D, Das A, et al. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51:3612-3616.
12. Corey GR, Wilcox MH, Talbot GH, et al. CANVAS1: The first Phase III, randomized, doubleblind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010;65(Suppl. 4):iv41-iv51.
13. Wilcox MH, Corey GR, Talbot GH, et al. CANVAS 2: The second Phase III, randomized, doubleblind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl. 4): Iv53-iv65.
14. File TM Jr, Low DE, Eckburg PB. et al. FOCUS 1: A randomized, doubleblinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in communityacquired pneumonia. J Antimicrob Chemother 2011;66(Suppl. 3):iii19-iii32.
15. Low DE, File TM Jr, Eckburg PB. et al.; FOCUS 2: A randomized, doubleblinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in communityacquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii33-iii44.
16. Beal SL, Sheiner LB, Boeckmann AJ. 2006; NONMEM users guides. ICON Development Solutions, Ellicott City, MD.
17. DuBois D, DuBois EF.Aformula to estimate the approximate surface area if height and weight be known. Arch Int Med. 1916;17:863-871.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
19. Williams PJ, Kim YH. Resampling techniques and their application to pharmacometrics. In: Ette EI, Williams PJ, eds. Pharmacometrics: The Science of Quantitative Pharmacology. Hoboken, NJ: John Wiley & Sons; 2007. pp. 401-419.
20. Efron B, Gong G. Aleisurely look at the bootstrap, the jackknife, and cross validation. Am Statistician. 1983;37(1):36-48.
21. Lindbom L, Pihlgren P, Jonsson EN. PsNToolkita collection of computer intensive statistical methods for nonlinear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79(3):241-257.
22. Bhavnani SM, Hammel JP, Van Wart SA, et al. Pharmacokineticpharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with complicated skin and skin structure infection. In: Abstracts of the FiftyFirst Interscience Conference on Antimicrobial Agents and Chemotherapy. 2011: A2552. Chicago, IL; September 2011.
23. Bhavnani SM, Hammel JP, Van Wart SA, et al. Pharmacokineticpharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with communityacquired pneumonia. In: Abstracts of the FiftyFirst Interscience Conference on Antimicrobial Agents and Chemotherapy. 2011: A2551. Chicago, IL; September 2011.
24. Bhavnani SM, Van Wart SA, Rubino CM, et al. Pharmacokineticpharmacodynamic target attainment analysis to evaluate susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus. In: Abstracts of the FiftyFirst Interscience Conference on Antimicrobial Agents and Chemotherapy. 2011: A2553. Chicago, IL; September, 2011.
25. VanWart SA,Ambrose PG, Rubino CR, et al.Use of ceftaroline against Streptococcus pneumoniae: Pharmacokinetic-pharmacodynamic target attainment analysis to evaluate susceptibility test interpretive criteria. In: Abstracts of the FiftyFirst Interscience Conference on Antimicrobial Agents and Chemotherapy. 2011: A2549. Chicago, IL; September, 2011.